Jubilant Life Sciences Q3 net up 80% to ₹212.84 cr

NEW DELHI: Drug firm Jubilant Life Sciences on Wednesday reported a 80.20% rise in its consolidated net profit to ₹212.84 crore for the third quarter ended December 2017 mainly on account of robust sales in Speciality Pharma — Injectables and Life Science Ingredients segments. The company had posted a net profit of ₹118.11 crore in the year-ago period.